The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

Spravato (esketamine) has been touted as a potential ... offer new hope to the estimated one-third of people with major depressive disorder who have not responded to existing therapies,” said ...

We identified 32 studies that met our inclusion criteria. Results: We found that the relative risk of developing a depressive disorder was incidence rate ratio = 0.79 (95% confidence interval ...

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

What are some ways the brain differs in people with depression? Studies of individuals with major depressive disorder have identified lower gray matter volume in a number of brain areas relative ...

In some studies, as many as one third of people with major depressive disorder had symptoms of agitation and physical restlessness. They may range from frequent wringing of the hands and shuffling ...